BSX
Income statement / Annual
Last year (2025), Boston Scientific Corp.'s total revenue was $20.07 B,
an increase of 19.87% from the previous year.
In 2025, Boston Scientific Corp.'s net income was $2.89 B.
See Boston Scientific Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$20.07 B |
$16.75 B |
$14.24 B |
$12.68 B |
$11.89 B |
$9.91 B |
$10.74 B |
$9.82 B |
$9.05 B |
$8.39 B |
| Cost of Revenue |
$6.22 B
|
$6.48 B
|
$5.41 B
|
$4.97 B
|
$4.43 B
|
$4.34 B
|
$3.86 B
|
$3.35 B
|
$3.18 B
|
$3.04 B
|
| Gross Profit |
$13.85 B
|
$10.27 B
|
$8.83 B
|
$7.71 B
|
$7.46 B
|
$5.58 B
|
$6.88 B
|
$6.48 B
|
$5.87 B
|
$5.34 B
|
| Gross Profit Ratio |
0.69
|
0.61
|
0.62
|
0.61
|
0.63
|
0.56
|
0.64
|
0.66
|
0.65
|
0.64
|
| Research and Development Expenses |
$2.05 B
|
$1.62 B
|
$1.41 B
|
$1.32 B
|
$1.20 B
|
$1.14 B
|
$1.17 B
|
$1.11 B
|
$997.00 M
|
$920.00 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.89 B
|
$5.98 B
|
$5.19 B
|
$4.52 B
|
$4.29 B
|
$3.79 B
|
$3.93 B
|
$3.56 B
|
$3.28 B
|
$3.08 B
|
| Other Expenses |
$943.00 M
|
$33.00 M
|
$46.00 M
|
$47.00 M
|
$49.00 M
|
$45.00 M
|
$65.00 M
|
$70.00 M
|
$68.00 M
|
$104.00 M
|
| Operating Expenses |
$9.88 B
|
$7.63 B
|
$6.65 B
|
$5.89 B
|
$5.54 B
|
$4.98 B
|
$5.17 B
|
$4.74 B
|
$4.35 B
|
$4.11 B
|
| Cost And Expenses |
$16.10 B
|
$14.11 B
|
$12.06 B
|
$10.86 B
|
$9.97 B
|
$9.31 B
|
$9.02 B
|
$8.09 B
|
$7.52 B
|
$7.15 B
|
| Interest Income |
$0.00
|
$107.00 M
|
$22.00 M
|
$10.00 M
|
$4.00 M
|
$3.00 M
|
$30.00 M
|
$3.00 M
|
$5.00 M
|
$5.00 M
|
| Interest Expense |
$349.00 M
|
$387.00 M
|
$272.00 M
|
$464.00 M
|
$349.00 M
|
$468.00 M
|
$513.00 M
|
$269.00 M
|
$230.00 M
|
$234.00 M
|
| Depreciation & Amortization |
$0.00
|
$1.27 B
|
$1.20 B
|
$1.14 B
|
$1.09 B
|
$1.12 B
|
$1.01 B
|
$894.00 M
|
$844.00 M
|
$815.00 M
|
| EBITDA |
$3.73 B |
$3.94 B |
$3.45 B |
$2.74 B |
$2.52 B |
$1.51 B |
$2.21 B |
$2.59 B |
$2.01 B |
$1.23 B |
| EBITDA Ratio |
0.19
|
0.24
|
0.24
|
0.22
|
0.21
|
0.15
|
0.21
|
0.26
|
0.22
|
0.15
|
| Operating Income Ratio |
0.2
|
0.16
|
0.15
|
0.14
|
0.16
|
0.06
|
0.16
|
0.18
|
0.17
|
0.15
|
| Total Other Income/Expenses Net |
-$586.00 M
|
-$353.00 M
|
-$196.00 M
|
-$683.00 M
|
-$846.00 M
|
-$680.00 M
|
-$1.03 B
|
-$315.00 M
|
-$592.00 M
|
-$1.06 B
|
| Income Before Tax |
$3.39 B
|
$2.28 B
|
$1.99 B
|
$1.14 B
|
$1.08 B
|
-$79.00 M
|
$687.00 M
|
$1.42 B
|
$933.00 M
|
$177.00 M
|
| Income Before Tax Ratio |
0.17
|
0.14
|
0.14
|
0.09
|
0.09
|
-0.01
|
0.06
|
0.14
|
0.1
|
0.02
|
| Income Tax Expense |
$493.00 M
|
$436.00 M
|
$393.00 M
|
$443.00 M
|
$36.00 M
|
$2.00 M
|
-$4.01 B
|
-$249.00 M
|
$828.00 M
|
-$170.00 M
|
| Net Income |
$2.89 B
|
$1.85 B
|
$1.59 B
|
$698.00 M
|
$1.04 B
|
-$82.00 M
|
$4.70 B
|
$1.67 B
|
$104.00 M
|
$347.00 M
|
| Net Income Ratio |
0.14
|
0.11
|
0.11
|
0.06
|
0.09
|
-0.01
|
0.44
|
0.17
|
0.01
|
0.04
|
| EPS |
1.96 |
1.26 |
1.0805 |
0.4488 |
0.6925 |
-0.0812 |
3.3776 |
1.21 |
0.08 |
0.26 |
| EPS Diluted |
1.94 |
1.25 |
1.0728 |
0.4459 |
0.687 |
-0.0812 |
3.3319 |
1.19 |
0.0747 |
0.25 |
| Weighted Average Shares Out |
$1.48 B
|
$1.47 B
|
$1.45 B
|
$1.43 B
|
$1.42 B
|
$1.42 B
|
$1.39 B
|
$1.38 B
|
$1.37 B
|
$1.36 B
|
| Weighted Average Shares Out Diluted |
$1.49 B
|
$1.49 B
|
$1.46 B
|
$1.44 B
|
$1.43 B
|
$1.42 B
|
$1.41 B
|
$1.40 B
|
$1.39 B
|
$1.38 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
